Nuwellis, Inc. Announces First Quarter 2022 Financial Results

May 10, 2022

MINNEAPOLIS, May 10, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the first quarter ended March 31, 2022, which included the following highlights:

Generated $1.9 million in total revenue for the first quarter 2022, up 17% sequentially from the fourth quarter of 2021
Received a Category III CPT Code effective January 1, 2022, specifically for the use of therapeutic ultrafiltration, thereby increasing reimbursement to professionals and facilities, an important step in advancing Aquadex to standard of care
On track to enroll first patients in REVERSE-HF, a randomized controlled multi-center clinical trial designed to validate clinical outcomes and the economic value of Aquadex therapy
First quarter 2022 cash flow from operations improved $0.6 million compared to the prior-year period

“I am very pleased with the resilient performance in the quarter,” said Nestor Jaramillo, CEO of Nuwellis. “Going forward, we expect to continue benefiting from the successful execution of our strategy and rollout of our new sales management system.”

First Quarter 2022 Financial Results

Total revenue for the first quarter of 2022 was $1.9 million, an increase of 17% compared to the fourth quarter of 2021 and even with the prior-year period. Growth in the quarter was fueled by higher sales of consumables. Capital equipment sales increased sequentially but were below the prior year, while total monthly year-on-year sales comparisons improved as the business advanced through the quarter.

Gross margin was 57.2% for the first quarter 2022, compared to 50.4% in the prior-year period, with the increase driven primarily by favorable product sales mix and reduced inventory revaluation expense.

Selling, general and administrative expenses for the first quarter of 2022 were $4.4 million, representing a 16% reduction compared to the prior-year period. This reduction resulted from continued cost vigilance and certain non-recurring administrative costs in the prior-year period.

First-quarter research and development expenses were $1.1 million dollars, compared to $0.9 million dollars in the first quarter of 2021. This increase reflects investment in our dedicated pediatric device.

The net loss for the first quarter of 2022 was $4.5 million, compared to a net loss of $5.2 million in the prior-year period. This resulted in $0.6 million lower net cash used in operating activities.

Cash and cash equivalents were approximately $19.3 million as of March 31, 2022.

Webcast and Conference Call Information
The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the Company’s performance. To access the live webcast, please visit http://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 6092276. An audio archive of the webcast will be available following the call at http://ir.nuwellis.com.

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow^® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, MN, with a wholly owned subsidiary in Ireland.

About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2022 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

NUWELLIS, INC. AND SUBSIDIARY
Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(In thousands, except per share amounts)

		Three months ended March 31,
		2022					2021
Net sales	$	1,926		$	1,918
Cost of goods sold		824			952
Gross profit		1,102			966
Operating expenses:
Selling, general and administrative		4,412			5,237
Research and development		1,106			947
Total operating expenses		5,518			6,184
Loss from operations		(4,416	)			(5,218		)
Other income (expense), net		(55	)			(1		)
Loss before income taxes		(4,471	)			(5,219		)
Income tax expense		(2	)			(2		)
Net loss	$	(4,473	)	$	(5,221			)

Basic and diluted loss per share	$	(0.42	)	$	(1.62			)

Weighted average shares outstanding – basic and diluted		10,538			3,242

Other comprehensive loss:
Unrealized foreign currency translation adjustments	$	(2	)	$	(3			)
Total comprehensive loss	$	(4,475	)	$	(5,224			)

NUWELLIS, INC. AND SUBSIDIARY
Consolidated Balance Sheets
(In thousands, except share and per share amounts)

		March 31, 2022			December 31, 2021
ASSETS		(unaudited)
Current assets
Cash and cash equivalents	$	19,300		$	24,205
Accounts receivable		951			750
Inventories		3,294			2,843
Other current assets		350			328
Total current assets		23,895			28,126
Property, plant and equipment, net		1,153			1,188
Operating lease right-of-use asset		1,038			1,082
Other assets		21			21
TOTAL ASSETS	$	26,107		$	30,417

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable	$	1,797		$	1,414
Accrued compensation		1,335			1,664
Current portion of operating lease liability		181			167
Current portion of finance lease liability		24			26
Other current liabilities		55			36
Total current liabilities		3,392			3,307
Operating lease liability		909			956
Finance lease liability		22			28
Other long-term liability		71			179
Total liabilities		4,394			4,470

Commitments and contingencies

Stockholders’ equity
Series A junior participating preferred stock as of March 31, 2022 and December 31, 2021, par value $0.0001 per share; authorized 30,000 shares, none outstanding		—			—
Series F convertible preferred stock as of both March 31, 2022 and December 31, 2021, par value $0.0001 per share; authorized 127 shares, issued and outstanding 127 shares		—			—
Preferred stock as of both March 31, 2022 and December 31, 2021, par value $0.0001 per share; authorized 39,969,873 shares, none outstanding		—			—
Common stock as of March 31, 2022 and December 31, 2021, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 10,537,606 shares		1			1
Additional paid-in capital		279,114			278,873
Accumulated other comprehensive income:
Foreign currency translation adjustment		(13	)		(11	)
Accumulated deficit		(257,389	)		(252,916	)
Total stockholders’ equity		21,713			25,947
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	26,107		$	30,417

NUWELLIS, INC. AND SUBSIDIARY
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(in thousands)

		Three months ended March 31,
		2022			2021
Operating Activities:
Net loss	$	(4,473	)	$	(5,221	)
Adjustments to reconcile net loss to cash flows used in operating activities:
Depreciation and amortization		105			126
Stock-based compensation expense, net		241			355
Changes in operating assets and liabilities:
Accounts receivable		(201	)		(14	)
Inventory		(451	)		(89	)
Other current assets		(22	)		(132	)
Other assets and liabilities		(80	)		24
Accounts payable and accrued expenses		54			(431	)
Net cash used in operating activities		(4,827	)		(5,382	)

Investing Activities:
Purchases of property and equipment		(70	)		(56	)
Net cash used in investing activities		(70	)		(56	)

Financing Activities:
Proceeds from public stock offerings, net		—			18,902
Proceeds from warrant exercises		—			1
Payments on finance lease liability		(6	)		(6	)
Net cash provided (used in) by financing activities		(6	)		18,897

Effect of exchange rate changes on cash		(2	)		(3	)
Net increase in cash and cash equivalents		(4,905	)		13,456
Cash and cash equivalents - beginning of period		24,205			14,437
Cash and cash equivalents - end of period	$	19,300		$	27,893

Supplemental cash flow information
Inventory transferred to property, plant and equipment	$	—		$	89